HepatologyNews.net

Hepatology Xagena

Search results for "Hepatitis B"

European Commission has approved Pegasys ( Peginterferon alfa-2a ) for the treatment of chronic hepatitis B. The approval is granted for both types of the disease, HBeAg-positive and HBeAg-negativ ...


The FDA ( Food and Drug Administration ) approved Baraclude ( Entecavir ) tablets and oral solution for the treatment of chronic hepatitis B in adults. Baraclude is indicated for the treatment of ...


The FDA ( Food and Drug Administration ) approved Pegasys ( Peginterferon alfa-2a ) for the treatment of chronic hepatitis B ( CHB ). Pegasys is the first and only pegylated Interferon approved fo ...


Patients with the most common form of hepatitis B in the United States who are treated with Pegasys ( Peginterferon alfa-2a ) are more likely to achieve a sustained response than those treated with La ...


The phase III GLOBE trial for Telbivudine ( Sebivo, Tyzeka ) successfully reached its primary, composite efficacy endpoint of therapeutic response at one year in chronic hepatitis B patients. This e ...


When a diseased liver is removed from a patient with hepatitis C (HCV), serum viral levels plummet. However, after receiving a healthy liver transplant, virus levels rebound and can surpass pre-tran ...


A study on treating hepatitis B patients who have cancer with an antiviral drug at the same time as they undergo chemotherapy found that the treatment helped prevent relapse of hepatitis B. Patient ...


A study on HIV patients who also had hepatitis B virus ( HBV ) found that better outcomes are possible if they are referred early for transplant and treated with a combination of drugs for HBV. It i ...


A study on the long-term outcome of children undergoing liver transplants found that chronic hepatitis was common and that it was not detectible using standard blood tests. The presence of autoantibo ...


The FDA ( Food and Drug Administration ) has announced the approval of HepaGam B for the prevention of hepatitis B reinfection in certain liver transplant patients. HepaGam B is an immune globulin ...


Researchers at The University of Texas MD Anderson Cancer Center have discovered that exposure to the hepatitis B virus ( HBV ) may increase the risk of pancreatic cancer.The study, published in the J ...


For patients with the most common form of hepatitis C, the addition of a hepatitis C–specific protease inhibitor called Telaprevir to the current standard therapy can significantly improve the chances ...


Epidemiological, genetic and clinical data presented at the International Liver Congress 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment ...


Entecavir ( Baraclude ) is effective and safe in patients with chronic hepatitis B in the short term, but its long term efficacy and safety has not been established. Researchers have evaluated HBV ...


A study has revealed that virological breakthrough is common in patients receiving nucleoside analogs ( NUCs ) for chronic hepatitis B. Nearly 40% of the virological breakthrough found were not relate ...